KALY - Kali Extracts To Release Report On Cannabis Extracts For COPD
February 04 2019 - 11:18AM
InvestorsHub NewsWire
By
ME Staff - February 4, 2019
Kali Extracts Inc. (OTCMKTS:KALY) has
announced that they are planning to give a presentation preview on
the impact of cannabis on COPD, or chronic obstructive pulmonary
disease. They have scheduled the presentation for tomorrow, the
5
th of February where Fred Ferril Kali’s CEO and
Professor Jeffry Osbourn of Kentucky University will publish the
preliminary results online.
Chronic Obstructive Pulmonary Disease
Kali has already released previous results of the vitro genomic
study. The study evaluated the effect of their pharmaceutical grade
cannabis extracts and a combination of other therapies in the
management of COPD patients.
In addition to the previous in vitro genomics
study, the company has equally finalized a long-term pilot study on
the use of pharmaceutical cannabis extracts in the treatment of
COPD in primates. The preliminary review of the results that the
company has scheduled for February 5th will provide further insight
into the ongoing primate study as the company waits to give a
comprehensive report on the study by March.
Kali product portfolio
Kali-Extracts focuses on health and wellness, and generates
revenue from a cannabis extraction platform that they have
patented.
The company is utilizing their patented cannabis extraction
technology to develop and process various wellness and health
products internally as well as through external partnerships. Also,
the company has been employing the patented cannabis extraction
technology in developing pharmaceutical products in house as well
as through collaborations with other companies.
Their extraction process is licensed to CBD-infused beverages
production company Puration, Inc. (OTCMKTS:PURA). Puration’s
twelve-month sales have been trailing at approximately $1 million,
and their sales of the EVERx CBD sports water is growing in
popularity.
Currently, Kali is working with Puration on the development of a
new 25mg CBD formulation that will be used by Puration to produce
new CBD-infused water. The two companies have signed a $1 million
agreement to jointly produce customized CBD infused drink
for Generex Biotechnology Corporation (OTCMKTS:GNBT). The new
GNBT drink will be available on the shelves soon.
Original Source: https://marketexclusive.com/kali-extracts-to-release-report-on-cannabis-extracts-for-copd/2019/02/
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Sep 2023 to Sep 2024